404 related articles for article (PubMed ID: 31195212)
1. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
Rimassa L; Danesi R; Pressiani T; Merle P
Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
[TBL] [Abstract][Full Text] [Related]
2. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.
Kim BH; Yu SJ; Kang W; Cho SB; Park SY; Kim SU; Kim DY
J Gastroenterol Hepatol; 2022 Mar; 37(3):428-439. PubMed ID: 34725855
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
4. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Schmidinger M; Danesi R
Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
[TBL] [Abstract][Full Text] [Related]
5. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.
Lai X; Wan Q; Jiao SF; Sun XC; Hu JF; Peng HW
Expert Opin Drug Saf; 2024 Mar; 23(3):287-296. PubMed ID: 37608525
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
[TBL] [Abstract][Full Text] [Related]
10. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
11. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
13. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
de Rosamel L; Blanc JF
Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib: A Review in Hepatocellular Carcinoma.
Heo YA; Syed YY
Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
[TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
17. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
Kim S; Abou-Alfa GK
Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
19. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma.
Nawa T; Katayama K; Kiyota R; Imai T; Abe Y; Hasegawa N; Takada R; Fukutake N; Ikezawa K; Sakakibara M; Fujita M; Ohkawa K
Clin J Gastroenterol; 2020 Apr; 13(2):247-251. PubMed ID: 31317371
[TBL] [Abstract][Full Text] [Related]
20. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
